Skip to main content
. 2008 Oct 14;99(9):1484–1492. doi: 10.1038/sj.bjc.6604717

Figure 3.

Figure 3

The survival curve shows a lower medium survival time of 20 months (15.0–24.0) in the subgroup of patients with strong KLK6 and KLK10 co-expression compared with patients without/weak expression of these kallikreins (29 months (22.8–35.8)) (P=0.031).